Vascular endothelial cells are a critical component of the hematopoietic microenvironment that regulates blood cell production. Recent studies suggest the existence of functional cross-talk between hematologic malignancies and vascular endothelium. Here we show that human acute myeloid leukemia (AML) localizes to the vasculature in both patients and in a xenograft model. A significant number of vascular tissue-associated AML cells (V-AML) integrate into vasculature in vivo and can fuse with endothelial cells. V-AML cells acquire several endothelial cell-like characteristics, including the upregulation of CD105, a receptor associated with activated endothelium. Remarkably, endothelial-integrated V-AML shows an almost fourfold reduction in proliferative activity compared with non-vascular-associated AML. Primary AML cells can be induced to downregulate the expression of their hematopoietic markers in vitro and differentiate into phenotypically and functionally defined endothelial-like cells. After transplantation, these leukemia-derived endothelial cells are capable of giving rise to AML. These novel functional interactions between AML cells and normal endothelium along with the reversible endothelial cell potential of AML suggest that vascular endothelium may serve as a previously unrecognized reservoir for AML.
INTRODUCTION
Despite recent advances in detecting the presence of minimal residual leukemia, it remains challenging to distinguish those patients who are cured from those destined to develop recurrent disease. 1, 2 Most studies of the potential mechanisms responsible for acute myeloid leukemia (AML) relapse have focused on identifying mutations and other leukemia cell intrinsic factors that confer drug resistance. Although it is well established that the tumor microenvironment is an important determinate of solid tumor initiation, progression and resistance to therapy, [3] [4] [5] relatively little is known about the role of the microenvironment in regulating the survival of acute leukemia.
Our previous studies of normal hematopoietic stem cells (HSCs) provided us with evidence that the functional relationship between hematopoiesis and vascular endothelium originally identified during early development persists into adult life. 6, 7 In both mice and humans, the adult HSC generates both blood and blood vessels. [8] [9] [10] [11] [12] Furthermore, recent reports show that vascular endothelial cells within the bone marrow microenvironment are important for regulating self-renewal and differentiation of HSCs and lineage-committed progenitors. [13] [14] [15] [16] [17] Interactions between the vascular niche and hematopoietic malignancies may therefore have an important role in the pathophysiology of leukemia. Supportive of this possibility, increased microvascular density is found in the bone marrow of patients with hematologic malignancies 18, 19 and may correlate with more aggressive disease. [20] [21] [22] [23] Functionally significant, cytokine-mediated crosstalk between endothelial cells and AML has been demonstrated in tissue culture. [24] [25] [26] [27] Thus, developing an in-depth understanding of interactions between the vascular microenvironment and malignant hematopoiesis is a promising area of investigation. 28 In this study we directly tested the possibility that AML functionally interacts with the vascular endothelium in vivo. Our results demonstrate that incorporation into the endothelial cell layer by attachment or cell fusion induces a relatively quiescent phenotype in AML cells. Moreover, AML cells that adopt endothelial cell characteristics have the potential to give rise to leukemia on transplantation. This previously unrecognized potential of AML to both closely associate with and integrate into vascular endothelium has important implications for disease relapse. Targeting the interactions between AML and endothelial cells may be therapeutically useful.
MATERIALS AND METHODS

Primary AML samples
Cells were obtained from AML patients undergoing leukapheresis or bone marrow aspiration after informed consent and in accordance with Oregon Health & Science University and University of Florida institutional review board policies. Cells were processed within 24 h of collection, cryopreserved in dimethylsulfoxide and stored in liquid nitrogen.
Xenotransplantation
NOD/LtSz-scid/IL2Rg c null (NSG) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained in a breeding colony under specific pathogen-free conditions in the animal care facilities at both 1 Division of Hematology/Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA;
institutions. Mice (8-12-week old) were irradiated with 200-250 cGy from a cesium irradiator immediately before transplant. Human AML cells (1-3 Â 10 6 cells per mouse) or AML-derived endothelial colony-forming cells (ECFCs) (1-3 Â 10 5 cells per mouse) were injected intravenously. Mice were allowed to drink freely for 6 days from water bottles containing 0.8 mg/ml Bromodeoxy uridine (BrdU; Sigma, St Louis, MO, USA), freshly prepared every other day.
ECFC culture
The ECFC protocol developed by Yoder and colleagues was employed. 29 AML cells were suspended in EGM-2 medium and plated in culture dishes coated with type 1 rat tail collagen (BD Biosciences, Bedford, MA, USA) at a density of 1 Â 10 6 to 1 Â 10 7 cells per well. Twenty-four hours after plating, non-adherent cells were removed and remaining adherent cells fed with fresh EGM-2 medium. Medium was changed every day for the first 7 days and then every other day until ECFCs were generated.
Immunostaining
Deparaffinized patient liver biopsy sections were stained with hCD33 (1:100; Novocastra, Davie, FL, USA) or hCD31 (1:100; Dako JC70A, Glostrup, Denmark) followed by goat anti-mouse biotin. Signal was detected by staining with horse radish peroxidase Elite Standard ABC reagent and a DAB staining kit (Vector Laboratories, Burlingame, CA, USA). For samples that were also stained with hCD45, the slides were incubated in phosphate buffered saline at 60 1C for 30 min, blocked and then incubated with antihCD45 (BD Biosciences), followed by goat anti-mouse biotin and detection with a Standard Alkaline Phosphatase ABC kit in conjunction with Vector Blue staining reagent (Vector Laboratories). Livers from xenografted mice were harvested, fixed in 4% paraformaldehyde, dehydrated in 30% sucrose and cryopreserved in optimal cutting temperature compound (Sakura Finetek, Torrance, CA, USA). Fixed femurs from xenografted mice were decalcified in 14% EDTA before cryopreservation. Sorted cells were allowed to settle overnight onto slides in 2% paraformaldehyde. Cells and tissue cryosections (5-7 microns) were incubated with blocking buffer (5% goat serum, 1% albumin from bovine serum, 0.05% Tween 20 in phosphate buffered saline) for up to 1 h, incubated overnight at 4 1C with rat antimCD31 (1:50; MEC13.3, BD Biosciences) and then stained with goat anti-rat Cyanine (Cy) 3 (1:200-1:400; Millipore Chemicon, Billerica, MA, USA). Slides were then incubated with mouse anti-hCD45 (1:100; clone HI30, BD Biosciences) for 1 h at room temperature, followed by goat anti-mouse conjugated to Alexa488 for 1 h (1:200-1:400; Invitrogen, Grand Island, NY, USA). Alternatively, cryosectioned livers were incubated in mouse anti-CD105 and isolectin GS-IB4 conjugated to Alexafluor 647 (1:25; Invitrogen) overnight at 4 1C, followed by goat anti-mouse Cy3. Sections were then stained with hHLA-ABC-biotin (1:100; eBioscience, San Diego, CA, USA), followed by streptavidin DyLight488 (1:100; Vector Laboratories). For BrdU labeling studies, cryosections were unmasked in 2 N HCl at 37 1C for 10 min, blocked with IMAGE-iT (Invitrogen) and incubated overnight with rat anti-BrdU (1:100; AbD Serotec, Raleigh, NC, USA) and isolectin GS-IB4 conjugated to Alexafluor 647, followed by goat anti-rat Cy3. All immunofluorescently labeled cells were counterstained with 4,6 diamino-2-phenylindole (DAPI) and mounted in FluoromountG (Southern Biotech, Birmingham, AL, USA). For immunofluorescence staining of AML-derived ECFCs, mouse antibodies directed against hCD14 (1:50; clone 2Q1233, Abcam, Cambridge, MA, USA), hCD45 (1:100; clone HI30, BD Biosciences) and hCD105 (1:50; clone 4G11, Abcam) were used. Following primary antibody incubation, cells were washed and exposed to donkey antimouse fluorescein isothiocyanate (FITC) secondary antibody (1:500; Invitrogen) for 1 h at room temperature in the dark. Cells were then washed and incubated with normal buffered formalin (Sigma) for 10 min, followed by a final rinse in Tris-buffered saline. For colorimetric detection of AML engraftment in mouse bone marrow, bones were decalcified, embedded in paraffin and sectioned, and an ARK kit (Dako) was employed following the manufacturer's instructions. Mouse anti-hCD45 (1:50; Dako) was applied for 20 min at 95 1C in Target Retrieval Solution (Dako), and positive signal was detected using DAB þ (Dako). Samples were counterstained with hematoxylin QS (Vector Laboratories).
Microscopy
Samples were examined and photographed with a Zeiss Axiophot 200 microscope with an Achroplan 40 Â 0.60 numerical aperture (NA) objective or an EC Plan 100 Â 1.3 NA Neofluor oil objective and a true color or a monochromatic AxioCam camera and standard epifluorescence filters for FITC,Cy3, Cy5 and DAPI (Zeiss, Thornwood, NY, USA). Images were digitally combined using Axio Vision software (Zeiss). Alternatively, samples were examined using a fluorescent Leica DM 2500 microscope (Leica Microsystems, Buffalo Grove, IL, USA), Â 10/0. 40 Flow cytometry and fluorescence-activated cell sorting Peripheral blood and bone marrow cells from xenografts were processed as previously described. 10 V-AML was isolated from bones that were crushed with a mortar and pestle and collagenased as described by Hooper et al. 30 Non-parenchymal cells from the liver of chimeric mice were generated essentially as described, 31 following a single collagenase digestion. Antibodies were purchased from BD Biosciences unless otherwise indicated. For human cell engraftment, mCD45.1-PE-Cy7 (eBioscience), hCD13-PE, hCD33-PE, hCD45-APC and hCD3-FITC were used and cells were analyzed with a BD FACSCalibur or a BD LSRII flow cytometer. Following staining with mCD45.1-FITC, hCD33-PE, hCD13-PE, mCD31-APC and V-AML cells were then isolated by fluorescence-activated cell sorting (FACS) using a BD InFlux with a 150-micron nozzle. ECFCs were stained with hCD14-APC, hCD146-PE, hCD105-PE (Invitrogen), hUEA-1-FITC (Sigma), hCD45-PE, hCD115-PE, hCD144-PE, or hVEGF-R2-PE (R&D Systems, Minneapolis, MN, USA). For Dil-ac-LDL (BD Biosciences) uptake, cells were incubated with 10 mg/ml Dil-ac-LDL in EGM-2 media for 4 h at 37 1C. Analysis was performed using a BD FACSCanto II flow cytometer. For all flow cytometry, dead cells were excluded using propidium iodide and scatter gates and doublets were excluded using the pulse width parameter.
Assessment of FLT3-ITD status in single cells
Nested PCR using the external FLT3 primers 5 0 -TCTGCAGAACTGCCTATT CCT-3 0 and 5 0 -AACTGTGCCTCCCATTTTTGTG-3 0 and the internal FLT3 primers 32 5 0 -CTTTCAGCATTTTGACGGCAAC-3 0 and 5 0 -GCAATTTAGGTATGA AAGCCAGC-3 0 was performed on DNA isolated from single cells, control DNA isolated from bulk populations of AML and mobilized peripheral blood cells from normal donors using a Qiagen (Germantown, MD, USA) DNeasy Kit according to the manufacturer's instructions. Single cells were sorted into 96-well PCR plates containing 5 ml DNA lysis buffer per well. Cell lysis was performed at 50 1C for 30 min, followed by 99 1C for 5 min. Singlecell DNA was amplified using 0.2 mM external primers at 96 1C for 5 min, followed by 10 cycles of 96 1C for 2 min, 55 1C for 1 min and 72 1C for 1 min, followed by an additional 25 cycles of 96 1C for 1 min, 55 1C for 1 min, 72 1C for 1 min and a final 72 1C elongation step for 3 min. Control DNAs (5 ng) were subject to the external PCR in a 25 ml volume, diluted 1:40 in nuclease-free water, and 5 ml was subsequently used for template in the internal nested PCR reaction using internal primers at a concentration of 0.2 mM under the following conditions: 95 1C for 3 min, followed by 35 cycles at 96 1C for 30 s, 56 1C for 30 s and 72 1C for 1 min. Amplicons were subject to electrophoresis on a 2% agarose DNA gel and photographed using a Bio-Rad (Hercules, CA, USA) Gel-Doc U.V. system. Table S1 ) and 1 ml 
Statistical analysis
Statistical significance was determined using an unpaired, two-tailed Student's t-test. P-values o0.05 were considered significant.
RESULTS
AML localizes to vascular endothelium in patients and xenografted mice
To dissect the functional relationship between AML and endothelium in vivo, primary human AML cells (Table 1) were transplanted into an immunodeficient NOD/SCID IL2Rg c null (NSG) mouse model (Figures 1a and b) . Typically, the frequency of AML cells was highest in the bone marrow, but the collapsed and distorted architecture of the marrow venous sinusoids precluded definitive localization of individual AML cells relative to the vascular endothelium (Figure 1c) . However, infiltrates of AML cells were also found in other tissues. The liver, a common site for extramedullary hematopoiesis in myeloproliferative disorders and myeloid leukemia, [33] [34] [35] consistently displayed relatively high levels of AML involvement and provided us with an opportunity to unambiguously study the relationship between AML cells and venous endothelium (Figure 1d ). Using species-specific antibodies, we identified a marked accumulation of AML cells near mouse endothelium (Figure 1e ). This leukemic infiltrate was particularly prominent around the portal veins, and herein, we will refer to these vessel-associated AML cells as V-AML.
To ensure that this finding of AML localization to portal vessels was not unique to our NSG xenograft model system, we evaluated liver tissue obtained from a cohort of 30 AML patients at autopsy. Seven patients (23%) showed a periportal infiltrate of AML. The pattern of leukemic infiltration in the human liver tissue (Figures  1f-h ) was indistinguishable from the AML infiltration in the liver of our NSG mouse model (Figures 1d and e) . In this cohort, one patient with newly diagnosed AML died before induction therapy could begin, a second had primary induction therapy failure and died within 5 weeks and the third patient had a long history of refractory AML. Therefore, perivascular liver involvement can be detected throughout the course of active disease in patients with AML. Clinically significant liver dysfunction attributable to AML is infrequent 36, 37 and none of the patients in our study demonstrated this. However, subclinical hepatic involvement is quite common and usually unrecognized. Specifically, in an autopsy series of 585 AML patients, 38 the frequency of perivascular liver involvement by AML at autopsy ranged from 28 to 71%. Taken together, our results show that a perivascular infiltration of the liver (V-AML) is a common finding in primary AML xenografts and in patients with AML.
AML binds to ECs and can integrate into vascular endothelium in vivo
High-resolution imaging of the livers of xenografted mice revealed a subset of V-AML cells that was tightly associated with mCD31 þ vascular endothelial cells in the portal vessels. Z-stack analysis confirmed colocalization of these human and mouse cell surface markers on the luminal side of the membrane of individual V-AML cells (Figures 2a and b) . These mCD31 þ hCD45 þ V-AML cells comprised up to 2% of the total portal endothelial cells (Figure 2c) . Importantly, when total bone marrow from primary recipients was harvested and transferred into secondary recipients, mCD31
þ V-AML cells were again readily detected in the liver, demonstrating that their capacity to generate V-AML is a conserved property of serially transplantable leukemic bone marrow (Figure 2c ). Figures 1-4 and Supplementary Figures 1-3 . Patients 8-10 were the source of autopsy liver samples shown in Figure 1 . Acute myeloid leukemia bone marrow samples from patients 10-16 were used in Figures 5-6 and Supplementary Figure 4 . WBC Â 10 3 per ml.
Using FACS (Figure 2d and Supplementary Figure 1A) , mCD31 þ V-AML was isolated from the livers of every AML-xenografted mouse tested (n ¼ 28). Nonspecific binding of mCD31 was specifically excluded by assaying primary AML samples before transplant (Supplementary Figure 1B) . Genomic analysis of single cells isolated from FLT3-ITD þ AML-recipient mice (n ¼ 6) revealed that 96% mCD31 þ V-AML cells harbored the FLT3-ITD (Figure 2e ), indicative of their leukemic origin. Consistent with the in situ liver studies (Figures 2a and b) , evaluation of sorted cell populations by immunofluorescence and confocal imaging demonstrated that nearly all individual sorted cells co-expressing mouse and human markers displayed a uniform hCD45 staining pattern with discrete patches of mCD31 þ membrane (Figure 2f and Supplementary  Figures 1C and D) . A bone marrow population of mCD31 þ V-AML cells with identical cell surface marker expression was also found (Supplementary Figure 2) . The distinct pattern of hCD45 and mCD31 co-expression in mCD31 þ V-AML cells is indicative of a very tight physical association and membrane coupling between AML cells and mouse endothelial cells in the bone marrow and liver.
A small subset of V-AML cells displayed a uniform, circumferential co-expression pattern of both hCD45 and mCD31 in both liver tissue sections (Figure 3a and Supplementary Figure 3A) and in sorted mCD31 þ V-AML cells (Figure 3b ). Some of these cells were binucleated (Figure 3b) , consistent with a cell fusion event. AML/mouse EC hybrid cells in which the expression of mouse and human markers did not overlap were also observed (Supplementary Figure 3B) . To assess cell fusion at the chromosomal level, we performed fluorescence in situ hybridization using species-specific pancentromeric probes. This approach revealed a subpopulation of sorted V-AML cells that contained both mouse and human centromeres (Figure 3c ), at the same frequency (B1% of total CD31 þ V-AML) fused/hybrid mouse EC and AML cells were identified using cell surface marker expression (Supplementary Figure 1D) .
V-AML expresses CD105 and adopts a quiescent phenotype in vivo
We and others have reported that the progeny of normal HSCs, including common myeloid progenitors, can integrate into existing functional vascular endothelium and express endothelial cell markers. [8] [9] [10] [11] [12] 39, 40 These findings, in addition to integration of V-AML into the vasculature shown above (Figures 2a and 3a) , raised the possibility that V-AML develops some endothelial characteristics. To investigate this further, we determined whether the tight association of AML cells with endothelium is correlated with their expression of endothelial cell-related genes. It is now recognized that many cell surface markers originally thought to be endothelial cell specific are also expressed in normal and malignant hematopoietic cells. 41, 42 Consequently, we first screened primary AML samples to identify those lacking the expression of individual endothelial-associated markers and then tested these samples further in vivo. Human endoglin (CD105) was the only one of eight endothelial markers that was not expressed in some of our patient samples (Supplementary Table 1) . Consistent with our hypothesis, sorted V-AML cells derived from CD105-negative primary AML samples had readily detectable CD105 mRNA expression by RT-PCR (Figure 4a) . In tissue sections, some AML cells closely associated with the endothelium in vivo also expressed CD105 (Figure 4b ). These results demonstrate that the close association of AML with endothelium can induce the expression of CD105, a membrane receptor associated with activated endothelium and tumor angiogenesis. 43 To investigate whether the integration of AML cells into vascular endothelium reduced their proliferative activity, AML-engrafted NSG mice were maintained on drinking water containing BrdU (Figure 4c 
6% of the mCD31
þ V-AML cells tightly associated with the portal vein endothelium were BrdU labeled (P ¼ 0.01). Interestingly, the low frequency of proliferating mCD31 þ V-AML cells was similar to the frequency observed in adjacent normal mouse CD31 þ endothelial cells. Together, our results demonstrate that a subpopulation of AML cells adopt certain endothelial characteristics, including integration into existing endothelium, CD105 expression and decreased proliferation.
AML can give rise to endothelial colony-forming cells in vitro AML cells were cultured using conditions that specifically support the growth of human endothelial progenitors, 29 also known as endothelial colony-forming cells (ECFC, Figure 5a ). Similar to normal endothelial cells and ECFCs, AML-derived ECFCs readily formed vascular tubes in the presence of Matrigel (Figure 5b) , demonstrated the uptake of acetylated low density lipoprotein, and expressed endothelial cell markers, including CD105, CD146, UEA-1 and VEGFR2 (Figure 5c and Supplementary  Figure 4) . ECFCs derived from AML cells also downregulated the expression of the pan-hematopoietic marker CD45 as well as the myeloid lineage markers CD14 and CD115. Consistent with their endothelial phenotype, AML-derived ECFC did not grow in standard myeloid colony-forming media. 44 To exclude a significant contribution from pre-existing normal endothelial progenitors, patient-specific AML markers were utilized. Fluorescence in situ hybridization analysis of single cells derived from these colonies revealed the presence of either trisomy 9 or the MLL gene rearrangement, the corresponding molecular marker for the individual patient's AML (Figure 5d generate cells with an endothelial-like phenotype at the clonal level. We will subsequently refer to these in vitro-generated, leukemia-derived endothelial colony-forming cells as L-ECFC.
AML-derived endothelium can adopt a leukemic phenotype The differentiation of AML into endothelial-like cells raises the intriguing possibility that vascular endothelium may represent a reservoir for occult residual leukemia. To begin to test this hypothesis, mCD31 þ V-AML cells isolated from the livers of chimeric mice (Figure 2d ) were transplanted into secondary NSGrecipients (3-10 Â 10 3 cells/mouse) and non-vascular-associated AML cells isolated from the same livers were also transplanted into NSG mice as a control (3 Â 10 4 cells/mouse). Neither population gave rise to detectable AML (data not shown). This result was not surprising as the frequency of leukemia-initiating cells is quite low. 45 By contrast, when L-ECFCs, which could be generated in large numbers from the bone marrow of AML patients, were transplanted into NSG recipients, the mouse bone marrow showed clusters of human CD45-expressing cells (Figures 6a-d ) that co-expressed the myeloid lineage marker CD33. The presence of molecular markers identified in the original, pre-transplant leukemia confirmed the leukemic origin of the L-ECFC-derived cells (Figures 6e and f) . These findings demonstrate that human AML-derived endothelial cells can retain leukemia-initiating potential in vivo despite initially downregulating their hematopoietic cell surface markers and adopting an endothelial cell-like phenotype.
DISCUSSION
In this study of the functional and developmental relationship between AML and endothelium, we identified a subset of AML that localizes to endothelium (V-AML) in vivo. Moreover, some V-AML cells physically integrate into the vasculature and become quiescent. Importantly, we demonstrate that AML cells with endothelial cell characteristics have the potential to give rise to leukemia on transplantation. Our results provide evidence that functional relationships between the vasculature and hematopoiesis may contribute to the pathophysiology of AML.
Several reports have shown that hematopoietic cells are capable of contributing to blood vessel formation, during embryonic development and in adults. 8, 10, 11, 40, 43, 46 In this study, we found that AML can adopt a spectrum of endothelial cell properties and that some AML cells integrate into the vasculature in xenografts, in part by a cell fusion mechanism. Moreover, standard endothelial progenitor cell culture conditions are capable of inducing primary AML cells to downregulate their hematopoietic phenotype and express a CD45 neg , CD105 þ , acLDL þ , VEGFR2 þ and UEA1 þ endothelial phenotype (L-ECFC). When transplanted into NSG recipients, these L-ECFC can convert back to their leukemic phenotype. Our findings of endothelial cell potential in AML are consistent with an intriguing study by Hoffman and colleagues, which evaluated the liver endothelium of patients with polycythemia vera. 35 They demonstrated the presence of the JAK2V617F mutation in isolated portal vein endothelial cells and concluded that this clonal myeloproliferative disorder, which often progresses to AML, involves primitive cells with the potential to differentiate into both hematopoietic and endothelial lineages. Together, these findings highlight that both normal and malignant myeloid cells have endothelial potential by at least two different mechanisms.
Normal HSCs are found in close proximity to vascular endothelium 13 and vascular endothelial cells are increasingly recognized as an important component of the normal and malignant hematopoietic microenvironments. 47, 48 Our study revealed that perivascular infiltration of the liver is common in primary AML xenografts and in patients with AML ( Figure 1) . These findings are similar to the reported high frequency of subclinical, liver involvement seen at autopsy 38 and the perivascular distribution of AML observed in patients with leukemic involvement of the skin. 49 Interestingly, we observed three classes of V-AML cells: AML cells adjacent to the endothelium; AML cells touching/adherent to the endothelium; and AML cells that are integrated into the endothelium. In both the liver and bone marrow of transplanted mice, V-AML cells were so tightly attached to host endothelial cells that extensive collagenase treatment did not disrupt the association between their cell membranes ( Figure 2 and Supplementary Figures 1-3) . The presence of these tightly adherent V-AML cells is consistent with the results of our previous studies of human AML cell lines and endothelium in vitro. 50 Previous studies suggested that proximity and adherence of AML cells to endothelium have dramatically different effects on AML cell behavior in vitro. Whereas the overall proliferation of most primary AMLs is increased when cultured in the presence of ECs, 25 we recently demonstrated that EC-adherent AML cells become quiescent in vitro relative to non-adherent AML cells. 50 Moreover, EC-adherent AML is less sensitive to cytarabine than non-adherent ECs. In our present in vivo study, V-AML cells attached to or integrated into the endothelial cell layer became quiescent relative to non-vascular-associated AML. Whether the small subpopulation of endothelial-AML cells produced by cell fusion is capable of proliferation in vivo remains to be determined. and anti-angiogenic therapy 52 cause regression of AML in experimental models. We have translated these findings into an ongoing phase I clinical trial of an anti-vascular agent, combretastatin, in patients with relapsed and refractory AML (ClinicalTrials.gov NCT0108656).
In conclusion, our results reveal alternative developmental fates of AML cells and support the hypothesis that leukemic cells can directly contribute to vascular endothelium. 51 Specifically, we show that AML can either differentiate into endothelial-like cells or fuse with established endothelium. Both of these fates may endow AML cells with pro-survival attributes. Our results strongly suggest that endothelium may serve as a previously unrecognized site of residual disease and lend further support to the concept of disrupting AML-endothelial cell interactions as a targeted therapeutic approach for AML. 
